Foundayo (orforglipron) approval creates the year's biggest new comparison opportunity

The U.S. Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity, or adults with overweight who have at least one weight-related medical condition, used along with a reduced-calorie diet and more physical activity ^[1]. It is a once-daily tablet from Eli Lilly and the first new molecular entity cleared under the agency's Commissioner's National Priority Voucher pilot program ^[1].

The review was unusually fast. The FDA said the decision came 50 days after filing and 294 days before the application's scheduled PDUFA date of January 20, 2027, making it the fastest approval of a new molecular entity since 2002 ^[1]. The agency has awarded 18 vouchers under the pilot and issued six decisions so far ^[1].

What the trials showed

Approval rested on two randomized, double-blind, placebo-controlled trials lasting 72 weeks in adults with obesity or overweight plus a weight-related condition ^[1]. In ATTAIN-1, which randomized 3,127 participants without diabetes, people on the highest dose who stayed on treatment lost an average of 27.3 pounds (12.4%), compared with 2.2 pounds (0.9%) on placebo ^[2]. Counting everyone who started the drug regardless of whether they finished the trial, the average loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo ^[2]. Those two ways of counting produce different placebo numbers, so the gap between drug and placebo is smaller in the second analysis. ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight and type 2 diabetes ^[2].

The label carries a boxed warning for thyroid C-cell tumors, and the drug is not for people with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2 ^[1]. Reported side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal distension, fatigue, burping, reflux, gas and hair loss ^[1]. Warnings also cover pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, low blood sugar, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, gallbladder disease and aspiration during anesthesia ^[1]. The FDA states it should not be used together with another GLP-1 receptor agonist ^[1].

The approved regimen is a starting dose of 0.8 mg, increased to 2.5 mg after at least 30 days, then 5.5 mg after another 30 days, with possible further steps to 9 mg, 14.5 mg or 17.2 mg based on response and tolerability ^[1].

Not semaglutide

Because Foundayo is a pill, it is being compared with oral semaglutide products. The two are different molecules. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist that can be taken any time of day without restrictions on food or water ^[2]; the FDA's acting CDER director described it as "a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach" ^[1]. Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus; tirzepatide is in Mounjaro and Zepbound. Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018 ^[2]. These sources do not include any head-to-head trial comparing orforglipron with semaglutide, so how they stack up directly is not yet known from this material.

Why it matters for patients

Cost and delivery are spelled out. Lilly says eligible people with commercial insurance may pay as little as $25 a month with a savings card, self-pay starts at $149 a month for the lowest dose, and eligible Medicare Part D enrollees may be able to pay $50 a month beginning as soon as July 1, 2026 ^[2]. Prescriptions are accepted immediately through LillyDirect with shipping starting April 6, followed by broad availability at U.S. retail pharmacies and through telehealth providers ^[2].

For people weighing options, the practical differences are the route (a daily tablet rather than a weekly injection), the absence of food and water timing rules ^[2], and a titration schedule that steps up over months ^[1]. Lilly's CEO said fewer than 1 in 10 people who could benefit from a GLP-1 are taking one ^[2]. Whether insurers will cover Foundayo, and on what terms, is not addressed in these sources. Safety and effectiveness in children are not known ^[2].

What happens next

The FDA will hold a public meeting on June 4, rescheduled from June 12, on the voucher program's criteria and procedures, with written comments accepted through June 29, 2026 ^[1]. Lilly says it has filed orforglipron for weight management and/or type 2 diabetes in more than 40 countries ^[2].